Taken together, our findings demonstrate that AMPK activation induced by skeletal 5-LO inhibition ameliorates murine insulin resistance, and highlight the possible therapeutic applications of 5-LO inhibition for the treatment of obesity-induced metabolic diseases like T2DM. Here, PRKAA1 is linked to obesity due to melanocortin 4 receptor deficiency.